Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles OncoImmunology Year : 2013

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

Abstract

The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.
Embargoed file
Embargoed file
Visibility date is undetermined
Loading...

Dates and versions

inserm-02440743 , version 1 (15-01-2020)

Identifiers

Cite

Marie Vincent, Agnès Quéméner, Yannick Jacques. Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. OncoImmunology, 2013, ⟨10.4161/onci.26441⟩. ⟨inserm-02440743⟩
23 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More